Ensuring Operational Feasibility in Next-Generation Oncology Trials

Rapid advances in oncology such as cell therapies, antibody-drug conjugates, biomarker-driven treatments, and increasingly adaptive trial designs (including basket, umbrella, and platform studies) are transforming how cancer drugs are developed. While these breakthroughs hold enormous promise, they also introduce new operational challenges related to patient identification, evolving protocols, specialized sites, complex logistics, and trial execution across multiple cohorts and arms.